Detalles de la búsqueda
1.
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Ther Drug Monit
; 46(3): 291-308, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38648666
2.
Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis.
Am J Gastroenterol
; 2023 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37753938
3.
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases.
Br J Clin Pharmacol
; 87(10): 3776-3789, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33604964
4.
Comparative Effectiveness Research to Position Therapies in Ulcerative Colitis: How Fair Are the Comparisons?
Clin Gastroenterol Hepatol
; 21(5): 1372-1373, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35850410
5.
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study.
Inflamm Bowel Dis
; 2024 Jan 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38215029
6.
Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's disease.
Therap Adv Gastroenterol
; 16: 17562848231189110, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37655059
7.
Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises.
Curr Res Pharmacol Drug Discov
; 3: 100089, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35146421
8.
Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
Eur J Gastroenterol Hepatol
; 34(10): 1015-1020, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36062494
9.
Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
Inflamm Bowel Dis
; 28(8): 1135-1142, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34751766
10.
Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All.
J Crohns Colitis
; 16(8): 1306-1320, 2022 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35150242
11.
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis.
J Crohns Colitis
; 16(10): 1562-1570, 2022 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35533353
12.
Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
Aliment Pharmacol Ther
; 56(2): 282-291, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35484689
13.
Breaking the therapeutic ceiling in drug development in ulcerative colitis.
Lancet Gastroenterol Hepatol
; 6(7): 589-595, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019798
14.
Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
Curr Opin Pharmacol
; 55: 17-30, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33039940
15.
Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease.
Inflamm Bowel Dis
; 2024 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38460148
16.
Ustekinumab and Vedolizumab Exposure Is Unaffected by Pharmacogenetic Determinants of Anti-TNFs Pharmacokinetics.
Inflamm Bowel Dis
; 30(5): 874-875, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38581670
17.
The Serum-Based Endoscopic Healing Index Can Monitor Therapeutic Response in Crohn's Disease.
J Crohns Colitis
; 17(10): 1703-1704, 2023 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37178692
18.
Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.
Aliment Pharmacol Ther
; 55(7): 885-886, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35315101
Resultados
1 -
18
de 18
1
Próxima >
>>